Samples

Revenue segments as reported by the company.

Test revenue

Other revenue

Revenue Segments

Gross Profit, Operating Income, and Net Income as a percentage of Revenue

Gross Margin

Operating Margin

Profit Margin

Margins

An operating expense is an expense a business incurs through its normal business operations. Often abbreviated as OPEX.

Change in fair value of contingent consideration

Asset impairment

Restructuring

Gain on sale of RUO kit assets

Operating Expenses

Year over year growth in Revenue and Operating Expenses.

Revenue Y/Y

OpEx Y/Y

Growth

Shares outstanding refer to a company's stock currently held by all its shareholders, including share blocks held by institutional investors and restricted shares owned by the company's officers and insiders.

Outstanding Shares

Market Cap

Also known as Price/Sales Ratio. Calculated using Average market cap for the quarter / Annualized quarterly revenue.

Revenue Multiple

Invitae

Invitae Corp. engages in the provision of genetic information into mainstream medical practice. It includes comprehensive panels for hereditary conditions in cancer, cardiology, neurology, pediatric, and rare diseases. The company was founded by Randal W. Scott and Sean E. George on January 13, 2010 and is headquartered in San Francisco, CA.

Earnings data Q1 2020

Earnings data Q2 2020

Earnings data Q3 2020

Earnings data Q4 2020

Earnings data Q1 2021

Earnings data Q2 2021

Earnings data Q3 2021

Earnings data Q4 2021

Earnings data Q1 2022

Earnings data Q2 2022

Earnings data Q3 2022

Earnings data Q4 2022

Earnings data Q1 2023

Earnings data Q2 2023

Earnings data Q3 2023

Earnings data Q1 2024

Invitae reports strong Q4 earnings, eyes growth amid challenges

Invitae's Q4 2022 performance showcased revenue growth, improved margins, and reduced cash burn, positioning the company for sustainable growth.
Strategic investments in key growth areas and a focus on customer experience and profitability underpin Invitae's vision for the future.
Addressing supply chain challenges while seizing opportunities for expansion and innovation will be critical for Invitae's continued success.

Invitae (NVTA) reports robust Q1 earnings and advances in PCM technology

Invitae's Q1 2023 earnings call highlighted strong financial performance, operational strengths, and strategic advancements in PCM technology.
The company's focus on growth, margin expansion, and debt management underscores a path towards sustainable profitability.
While facing challenges in reimbursement dynamics and competitive landscape, Invitae remains poised to capitalize on growth opportunities.

Invitae reports Q2 revenue growth, adjusts guidance amid challenges

Invitae shows progress towards profitability with improved margins and reduced cash burn.
Challenges in hereditary cancer revenue and PGX exit impact revenue guidance.
Focus on expanding customer base, improving reimbursement, and reducing cash burn.
Continuous investment in products for future growth and competitiveness.

Invitae reports robust Q3 earnings, addresses financial concerns proactively

Invitae's Q3 2023 performance was strong, with revenue growth and margin expansion. The company faces challenges in capital structure and insurance payments but is actively addressing them. Opportunities lie in revenue growth, operational improvements, and expanding genetic testing services.

Revenue

Cost of revenue

Gross profit

Operating expenses

SG&A

Other

Operating income

EBITDA

Net income

Earnings per share

Total assets

Current assets

Cash & equivalents

Receivables

Inventory

Non-current assets

Net PPE

Intangibles

Total liabilities

Current liabilities

Short term debt

Income tax payable

Non-current liabilities

Long-term debt

Total equity

Stockholders equity

Minority interest

Total liabilities & equity

Total debt

Net debt

Book value per share

Cash from operations

Funds from operations

Change in working capital

Cash from investing

Capital expenditure

Purchase/sale of investments

Purchase/sale of business

Other sources

Cash from financing

Change in stock

Change in debt

Cash dividends paid

Cash from other sources

Net change in cash

Free cash flow

Invitae is a genetic information company whose mission is to bring genetic information into routine medical practice to improve the quality of healthcare for billions of people.  Specializing in genetic diagnostics for hereditary disorders, Invitae is aggregating the world’s genetic tests into a single service with better quality, faster turnaround time, and a lower price than most single-gene diagnostic tests today.  What’s our plan? It takes three steps:  --Make genetic testing more affordable and accessible than ever before. --Build a secure and trusted genome management infrastructure. --Design a new global community for sharing genetic information to advance science and medicine.  Today, we are reinventing genetic testing by lowering the barriers for clinicians and patients to obtain diagnostic genetic information. Together we can improve healthcare for billions of people.

Cleveland-Cliffs

Twitter

Walmart

Walmart, Twitter, Cleveland Cliffs and Invitae are our top stock trades for Wednesday. Here's what the charts say about them going forward.

4 Top Stock Trades for Wednesday: TWTR, WMT, CLF, NVTA

COO of Invitae Corp (30-Year Financial, Insider Trades) E Lee Bendekgey (insider trades) sold 21,265 shares of NVTA on 08/19/2019 at an average price of $25.29 a share.

Invitae Corp (NVTA) COO E Lee Bendekgey Sold $537,792 of Shares

Biogen

CAMBRIDGE, Mass. and SAN FRANCISCO, Aug.  20, 2019  (GLOBE NEWSWIRE) -- Biogen Inc. (Nasdaq: BIIB) and Invitae Corporation (NYSE: NVTA) today announced that SMA STAT, a new, rapid-turnaround genetic test for spinal muscular atrophy (SMA), will be offered at no charge to individuals in the U.S. as part of the SMA Identified program. The SMA STAT test reduces the time needed for genetic testing to help confirm a definitive diagnosis of SMA from 21 to four days, enabling individuals and physicians to plan and begin treatment earlier for what is often a life-threatening disease. Clinical studies have demonstrated that early diagnosis and treatment of SMA may prevent the development of severe symptoms, improve motor function and slow the progression of the disease.

Biogen and Invitae Announce Availability of Rapid Results in Genetic Testing Program for Spinal Muscular Atrophy (SMA) to Improve Speed of Diagnosis for Patients

CVS Health

iShares 20+ Year Treasury Bond ETF

Micron Technology

Weightwatchers International Inc.

Bonds, CVS Health, Invitae, Micron and Weight Watchers were our top stock trades on Wednesday. Here's how to trade them.

5 Top Stock Trades for Thursday: TLT, WW, CVS, NVTA, MU

Invitae Corporation (NVTA) CEO Sean George on Q2 2019 Results - Earnings Call Transcript

Exact Sciences

Genomic Health

NeoGenomics

It was a great month to be a genetic testing company.

Here's Why Genetic Testing Stocks Rose as Much as 25.4% in July

Capital One

PepsiCo

Pfizer

Under Armour

Under Armour, PepsiCo, Invitae, Capital One and Pfizer are our top stock trades for Wednesday. Here's how to trade them.

5 Top Stock Trades for Wednesday (July 31)

Invitae (NVTA) expects to deliver a strong second quarter, banking on solid performance of its genetic testing business.

Will Genetic Testing Drive Invitae's (NVTA) Q2 Earnings?

Abbott Labs

SPDR Gold Trust

Teva Pharmaceutical

Tesla

Tesla, Teva, Abbott Labs, Invitae and the gold ETF were are top stock trades on Wednesday. Let's look at the setups heading into Thursday.

5 Top Stock Trades for Thursday (July 18)

After purchasing Singular Bio in June, InVitae Corp (NYSE: NVTA) now plans to acquire Jungla, which would add to its hereditary cancer testing capabilities, according to Benchmark.

InVitae Analyst: Acquisition Beefs Up Company's Hereditary Cancer Testing Capacity

Invitae (NVTA) saw a big move last session, as its shares jumped more than 9% on the day, amid huge volumes.

Invitae (NVTA) Catches Eye: Stock Jumps 9.1%

Apple

Exxon Mobil

Trade Desk

Apple, Nio, Exxon Mobil, Invitae and The Trade Desk are our top stock trades for Monday. See what their charts look like now.

5 Top Stock Trades for Monday: Apple, Exxon and more..

Myriad Genetics

Wall Street soured on the high-growth industry after first-quarter earnings were reported, but it may have been an overreaction for two stocks.

Here's Why Genetic Testing Stocks Lost as Much as 26.1% in May

Tucows

These three businesses may not be household names, but someday they could be.

High-Growth Stocks That Are Just Getting Started

Electronic Arts

Etsy

Stamps.com

Stamps.com is down 50%, Invitae, while The Trade Desk, Electronic Arts and Etsy are on the move. Here are our top stock trades for Friday.

5 Top Stock Trades for Friday, Including EA

Management thinks the company is on track for $500 million in revenue in 2020, but achieving that will require considerable capital investment.

Invitae Delivers Strong Growth in First Quarter, Readies Investment Surge

Sales slipped from the fourth quarter, but there's still a lot to like about this company.

Were Invitae's Quarterly Results Really That Bad?

The genetic testing leader and Wall Street weren't on the same page for first-quarter 2019 revenue.

Here's Why Invitae Got Crushed Today

Invitae Corporation (NVTA) CEO Sean George on Q1 2019 Results - Earnings Call Transcript

Invitae Corp.  shares plummeted more than 10% in the extended session Tuesday after the company missed sales estimates.

Invitae stock falls more than 10% after revenue miss

UnitedHealthcare just created a "Preferred Laboratory Network (PLN)".

Invitae Gets A Boost From A Mega Insurer

bluebird bio

Bristol-Myers

Celgene

CRISPR Therapeutics

Editas Medicine

Guardant Health Inc

Gilead Sciences

Illumina

Novartis

Spark Therapeutics

Pacific Biosciences of California

REGENXBIO

Roche Holding AG

Thermo Fisher Scientific

These next-generation companies are working on game-changing ways to obtain and profit from genetic insight.

Top Gene-Sequencing Stocks for 2019

These fast-growing companies are leveraging advances in genetic insight in ways that could pay off big for investors.

3 High-Growth Genomics Stocks You Can Buy

The company's making progress in its goal to make genetic screening for healthcare available to everyone.

News for Invitae Stock (NVTA)